Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK stock opened at $1.63 on Friday. The company has a market capitalization of $9.54 million, a price-to-earnings ratio of -0.54 and a beta of 0.39. Check-Cap has a 52-week low of $1.61 and a 52-week high of $4.59. The company has a 50-day simple moving average of $1.90 and a two-hundred day simple moving average of $2.11.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.